Background: Prostate cancer was the cause of death for around 358,989 (3.8%) of all cancer deaths in men in 2018. In Indonesia in 2020 there were around 7.4% of new cases of prostate cancer from all malignancies and about 2.1% of them end in death. MUC1 is a transmembrane glycoprotein that can be expressed in prostate adenocarcinoma. Several studies have shown that excessive and aberrant MUC1 expression can be found in prostate malignancies with a worse degree of malignancy. In addition, recently MUC1 is also considered to be a therapeutic target in prostate malignancy because MUC1 plays a role in cell proliferation, apoptosis and cell adhesion, so several studies are being carried out to determine the effectiveness of this protein as an alternative treatment for prostate malignancy. Objective:To examine MUC1 expression and the immunoreactivity pattern of MUC1 expression on histopathological grading of prostate adenocarcinoma Materials and Method: This research is an analytic study with a cross sectional approach. The sample in this study was a prostate adenocarcinoma slide stained with MUC1 immunohistochemistry which was assessed for its expression in three categories, namely negative, weak positive and strong positive and the immunoreactivity pattern of expression with three patterns, namely apical, diffuse cytoplasm and mixed. Result: There is no correlation between MUC1 expression and immunoreactivity pattern on histopathological grading of prostate adenocarcinoma.

prostate adenocarcinoma

MUC1

grade group gleason